Ray Liu Presents Vena Vitals at LSI USA ‘23

Transcription

Good morning everyone. My name is Ray Liu. I'm CEO and co founder of Vena Vitals. So Vena Vitals, we make a small wearable device that monitors blood pressure continuously. We're a clinical stage company, we're backed by Y Combinator and Medtech Innovator amongst others as well. So cardiovascular disease is the number one killer in the world, and blood pressure is its most important risk factor. But for something so critical as blood pressure, our tools today, for monitoring it are quite limited. We have the traditional cuff, but that gives us only snapshots in time, even though our blood pressures are constantly changing, whether that's on the operating table, or in our daily lives. Now, the only way to measure continuous changes in blood pressure is through an arterial line. But that involves jabbing a catheter directly into your artery. Not only is that a painful procedure, but it also requires a skilled physician to perform. And it introduces a number of potential complications and risk factors. So what we've done at Vena Vitals is solve these problems by being able to bring continuous non invasive blood pressure monitoring in the form of a wearable device that's conforming to the skin, and provides a very accurate measure of continuous b2b blood pressure. So how does it work? Well, it's, as your blood is flowing through your artery, it's pushing up against your arterial walls, which then applies pressure to your skin. And that's where our advanced sensor technology is detecting exactly that pressure that's pushing up against your skin. The material, it's a material science technology, and it's extremely sensitive. And we're able to manufacture these devices at 60 cents per sensor. So how well does it work? So this is an example of one of our very first clinical studies, one of our very first patients in the operating room compared head to head against the arterial line. You can see here that the arterial line measurement is on top and ours is below and we're tracking near perfectly. We're capturing each and every breath, every heartbeat, as well as in the middle. When the incision happens, blood pressure shoots up a bit, and we're tracking all of those changes. So what this means is two things. First, we're able to replace an invasive procedure that's still being performed in the US more than 8 million times per year. That's per year in the US alone. And second, because of our wearable form factor and our ease of use, we can actually bring continuous b2b blood pressure monitoring out of the hospital setting into other applications, such as sleep monitoring, and remote patient monitoring. And to drill into accuracy a bit further, you can see here, this is one of our patients in a coronary artery bypass procedure. And these patients, these cardiac patients have a lot of anomalies in their heart function. So not the easiest to measure. But again, we're matching the arterial line near perfectly. And when we zoom in to the actual waveforms themselves, you can see that we're tracking even throughout the different phases of the surgery from pre induction to post vascular to post anesthesia induction, as well as during vessel presser delivery. If we zoom out in the other direction, the story is just as compelling. So this is a five hour surgery, an ent procedure, where the patient has pretty wild swings in blood pressure, what you're seeing is 70 millimeters of mercury changes in both directions. And we're tracking it extremely well. What's really remarkable about this case is that you can see in the accelerometer, there's also a lot of motion going on. And our device for the entire five hours, we didn't need a single recalibration. So we are a clinical Stage Company. Thus far, we've already tested on more than 200 subjects in the operating room head to head against the arterial line, which is well beyond what the FDA requires for their clinical needs. But for us, it's really about proving a use case as needed for hospitals. And that's to be able to get adoption from physicians and from hospitals to use your product. And there, the requirements are a lot more rigorous. And really what they want to see is a wide range of patient populations, different ages, BMI size, as well as blood pressure ranges to be able to measure at the high and low ranges. And that's what we're laser focused and well on our way to achieve. So the market for blood pressure monitoring is enormous as you can imagine, because blood pressure is used everywhere from the hospital to the home. And there's over a billion people around the world who suffer from hypertension, who currently don't have a good tool to help them monitor and manage their condition. But we don't intend to boil the ocean all at once and worse. Learning in our roadmap where blood pressure, specifically continuous blood pressure is utilized the most today. And that's in the hospital in the operating rooms at ICU, we've also just expanded into a second beachhead market, which is in sleep monitoring. And that's because we've gotten some really compelling clinical data and sleep. And we've gotten an NIH grant to further develop this area. In the future, we do intend for our technology to become the premier standard for patient monitoring for chronic condition management. Now, I do want to drill into sleep for a minute here, because what we're doing and sleep monitoring is profound. Never before has anyone been able to measure blood pressure during sleep, because as soon as you put a cuff on somebody that's going to wake up the patient, or at least it'll interfere with their sleep. But sleep disorders such as sleep apnea, and cardiovascular disease are inextricably linked. And that's because whenever you have an apneic event, you stop breathing, well, that means your heart has to work extra hard to be able to recover from that event. And that's called your sympathetic response, which has never been possible to be able to measure before. And we're doing exactly that. So what you see in the image here in the chart here is the blue bands. Those are actual sleep apnea events that a physician, a sleep physician scored. And then our signal in red on top is a blood pressure response. And you can see, sure enough after each and every APNIC event, there's a corresponding subsequent surge in blood pressure. It's unprecedented to be able to measure this, when we showed this data to the head of the NIH sleep director, her exact words were that I'm drooling at your data. And to put it more succinctly, on the left is a is a blood pressure variability profile for a healthy subject during sleep. And on the right is a blood pressure variability profile for a patient who has been diagnosed with obstructive sleep apnea, who has been prescribed a CPAP, who hasn't been using it for about a year, which is an all too common story. And what you're seeing here is a direct view of the actual cardiovascular stress that's being placed on his body throughout the night as he's sleeping. Now, as a company, we're only a three year old company, but we've accomplished a lot in these three years, we raised a total of seven and a half million. And that's helped us accelerate our development into two beachhead markets in the hospital space, as well as in the sleep space. We currently do have a small round that's open is filling up, about a million remaining on that round. And then in about a year is when we plan to do our Series A we're will target 15 million. After we we complete our FDA 510 510 K clearances for both markets. If you're interested in either of these, feel free to reach out to me in the partnering app. And finally, I'll leave you with our team which is our most important asset. So not only do we have large company discipline from the likes of GE Healthcare, Siemens and Qualcomm, we also have some real entrepreneurial chops, having launched and sold companies to Cigna and vizient in the past, but more importantly, we're on the bleeding edge of transforming something so critical as blood pressure monitoring. And we'd love to have you join us for the journey. Thank you.